INMODE LTD
INMDNASDAQTrading Snapshot
- Day Range
- $14.04 β $14.33
- 52-Week Range
- $12.72 β $16.74
- Volume
- $1.87B
- Avg Volume
- $1.34B
- Shares Outstanding
- 57.5M
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $370M
- Last Q Revenue
- $96M
- P/E Ratio
- 11.4
- P/S Ratio
- 2.2x
- EPS (TTM)
- $1.32
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β12.0%
Why Investors Own INMD
- βHigh-growth profile β revenue up +16.4% YoY with expanding US Equity exposure.
- βHealthy economics β 53% gross margin and 28% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INMODE LTD
INMDAbout INMODE LTD
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates

InMode: Hope Is Not An Effective Investment Strategy, But Neither Is Despair
InMode remains rangebound as US platform sales decline, but international growth and recurring consumables revenue provide stabilization. I maintain a 'buy' rating, downgraded from 'strong buy,' citing cyclical industry

Reviewing InMode (NASDAQ:INMD) & LogicMark (OTCMKTS:LGMKD)
LogicMark (OTCMKTS:LGMKD - Get Free Report) and InMode (NASDAQ: INMD - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of t

Financial Analysis: IDEXX Laboratories (NASDAQ:IDXX) vs. InMode (NASDAQ:INMD)
InMode (NASDAQ: INMD - Get Free Report) and IDEXX Laboratories (NASDAQ: IDXX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strengt

InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool
IRVINE, Calif., Sept. 9, 2026 /PRNewswire/ --Β InMode Ltd.

InMode (NASDAQ:INMD) Stock Crosses Above Two Hundred Day Moving Average β Whatβs Next?
InMode Ltd. (NASDAQ: INMD - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $14.26 and traded as high as $15.20

A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture P